Gerard C. Blobe - Publications

Duke University, Durham, NC 
Molecular Biology, Oncology, Cell Biology

53 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Zhao F, Evans KS, Xiao C, DeVito N, Theivanthiran B, Holtzhausen A, Siska PJ, Blobe GC, Hanks BA. Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGF-β Inhibitor Sequencing in Melanoma. Cancer Immunology Research. PMID 30209062 DOI: 10.1158/2326-6066.CIR-18-0086  0.6
2016 Cribb JA, Osborne LD, Beicker K, Psioda M, Chen J, O'Brien ET, Taylor Ii RM, Vicci L, Hsiao JP, Shao C, Falvo M, Ibrahim JG, Wood KC, Blobe GC, Superfine R. An Automated High-throughput Array Microscope for Cancer Cell Mechanics. Scientific Reports. 6: 27371. PMID 27265611 DOI: 10.1038/srep27371  1
2015 Ehanire T, Ren L, Bond J, Medina M, Li G, Bashirov L, Chen L, Kokosis G, Ibrahim M, Selim A, Blobe GC, Levinson H. Angiotensin II stimulates canonical TGF-β signaling pathway through angiotensin type 1 receptor to induce granulation tissue contraction. Journal of Molecular Medicine (Berlin, Germany). 93: 289-302. PMID 25345602 DOI: 10.1007/s00109-014-1211-9  1
2014 Osborne LD, Li GZ, How T, O'Brien ET, Blobe GC, Superfine R, Mythreye K. TGF-β regulates LARG and GEF-H1 during EMT to affect stiffening response to force and cell invasion. Molecular Biology of the Cell. 25: 3528-40. PMID 25143398 DOI: 10.1091/mbc.E14-05-1015  1
2014 Gatza CE, Elderbroom JL, Oh SY, Starr MD, Nixon AB, Blobe GC. The balance of cell surface and soluble type III TGF-β receptor regulates BMP signaling in normal and cancerous mammary epithelial cells. Neoplasia (New York, N.Y.). 16: 489-500. PMID 25077702 DOI: 10.1016/j.neo.2014.05.008  1
2014 Elderbroom JL, Huang JJ, Gatza CE, Chen J, How T, Starr M, Nixon AB, Blobe GC. Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion. Molecular Biology of the Cell. 25: 2320-32. PMID 24966170 DOI: 10.1091/mbc.E13-09-0524  1
2014 Knelson EH, Gaviglio AL, Nee JC, Starr MD, Nixon AB, Marcus SG, Blobe GC. Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth. The Journal of Clinical Investigation. 124: 3016-31. PMID 24937430 DOI: 10.1172/JCI74270  1
2014 Meyer AE, Gatza CE, How T, Starr M, Nixon AB, Blobe GC. Role of TGF-β receptor III localization in polarity and breast cancer progression. Molecular Biology of the Cell. 25: 2291-304. PMID 24870032 DOI: 10.1091/mbc.E14-03-0825  1
2014 Knelson EH, Nee JC, Blobe GC. Heparan sulfate signaling in cancer. Trends in Biochemical Sciences. 39: 277-88. PMID 24755488 DOI: 10.1016/j.tibs.2014.03.001  1
2014 Holtzhausen A, Golzio C, How T, Lee YH, Schiemann WP, Katsanis N, Blobe GC. Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 28: 1248-67. PMID 24308972 DOI: 10.1096/fj.13-239178  0.6
2014 Strickler JH, McCall S, Nixon AB, Brady JC, Pang H, Rushing C, Cohn A, Starodub A, Arrowood C, Haley S, Meadows KL, Morse MA, Uronis HE, Blobe GC, Hsu SD, et al. Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Investigational New Drugs. 32: 330-9. PMID 24173967 DOI: 10.1007/s10637-013-0042-9  1
2014 Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, Sharma S. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 480-9. PMID 24173543 DOI: 10.1158/1078-0432.CCR-13-1840  1
2013 Hanks BA, Holtzhausen A, Evans KS, Jamieson R, Gimpel P, Campbell OM, Hector-Greene M, Sun L, Tewari A, George A, Starr M, Nixon A, Augustine C, Beasley G, Tyler DS, ... ... Blobe GC, et al. Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. The Journal of Clinical Investigation. 123: 3925-40. PMID 23925295 DOI: 10.1172/JCI65745  1
2013 Uronis HE, Bendell JC, Altomare I, Blobe GC, Hsu SD, Morse MA, Pang H, Zafar SY, Conkling P, Favaro J, Arrowood CC, Cushman SM, Meadows KL, Brady JC, Nixon AB, et al. A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. The Oncologist. 18: 271-2. PMID 23485624 DOI: 10.1634/theoncologist.2012-0404  1
2012 Vlahovic G, Meadows KL, Uronis HE, Morse MA, Blobe GC, Riedel RF, Zafar SY, Alvarez-Secord A, Gockerman J, Starodub AN, Ready NE, Anderson EL, Bendell JC, Hurwitz HI. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemotherapy and Pharmacology. 70: 95-102. PMID 22638798 DOI: 10.1007/s00280-012-1889-8  1
2012 Lee NY, Golzio C, Gatza CE, Sharma A, Katsanis N, Blobe GC. Endoglin regulates PI3-kinase/Akt trafficking and signaling to alter endothelial capillary stability during angiogenesis. Molecular Biology of the Cell. 23: 2412-23. PMID 22593212 DOI: 10.1091/mbc.E11-12-0993  0.6
2012 Townsend TA, Robinson JY, How T, DeLaughter DM, Blobe GC, Barnett JV. Endocardial cell epithelial-mesenchymal transformation requires Type III TGFβ receptor interaction with GIPC. Cellular Signalling. 24: 247-56. PMID 21945156 DOI: 10.1016/j.cellsig.2011.09.006  0.48
2011 Gatza CE, Holtzhausen A, Kirkbride KC, Morton A, Gatza ML, Datto MB, Blobe GC. Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth. Neoplasia (New York, N.Y.). 13: 758-70. PMID 21847367  0.88
2011 Altomare I, Bendell JC, Bullock KE, Uronis HE, Morse MA, Hsu SD, Zafar SY, Blobe GC, Pang H, Honeycutt W, Sutton L, Hurwitz HI. A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. The Oncologist. 16: 1131-7. PMID 21795432 DOI: 10.1634/theoncologist.2011-0078  1
2011 Swaminathan V, Mythreye K, O'Brien ET, Berchuck A, Blobe GC, Superfine R. Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines. Cancer Research. 71: 5075-80. PMID 21642375 DOI: 10.1158/0008-5472.CAN-11-0247  1
2011 Lambert KE, Huang H, Mythreye K, Blobe GC. The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells. Molecular Biology of the Cell. 22: 1463-72. PMID 21411633 DOI: 10.1091/mbc.E10-11-0877  1
2011 Bullock KE, Petros WP, Younis I, Uronis HE, Morse MA, Blobe GC, Zafar SY, Gockerman JP, Lager JJ, Truax R, Meadows KL, Howard LA, O'Neill MM, Broadwater G, Hurwitz HI, et al. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemotherapy and Pharmacology. 67: 465-74. PMID 21079958 DOI: 10.1007/s00280-010-1507-6  1
2010 Jima DD, Zhang J, Jacobs C, Richards KL, Dunphy CH, Choi WW, Au WY, Srivastava G, Czader MB, Rizzieri DA, Lagoo AS, Lugar PL, Mann KP, Flowers CR, Bernal-Mizrachi L, ... ... Blobe GC, et al. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood. 116: e118-27. PMID 20733160 DOI: 10.1182/blood-2010-05-285403  1
2010 Dugan E, Truax R, Meadows KL, Nixon AB, Petros WP, Favaro J, Fernando NH, Morse MA, Blobe GC, Hurwitz HI. A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors. Anticancer Research. 30: 1251-6. PMID 20530436  1
2010 Gatza CE, Oh SY, Blobe GC. Roles for the type III TGF-beta receptor in human cancer. Cellular Signalling. 22: 1163-74. PMID 20153821 DOI: 10.1016/j.cellsig.2010.01.016  0.6
2010 Randrianarison-Huetz V, Laurent B, Bardet V, Blobe GC, Huetz F, Duménil D. Gfi-1B controls human erythroid and megakaryocytic differentiation by regulating TGF-beta signaling at the bipotent erythro-megakaryocytic progenitor stage. Blood. 115: 2784-95. PMID 20124515 DOI: 10.1182/blood-2009-09-241752  1
2010 Ray BN, Lee NY, How T, Blobe GC. ALK5 phosphorylation of the endoglin cytoplasmic domain regulates Smad1/5/8 signaling and endothelial cell migration. Carcinogenesis. 31: 435-41. PMID 20042635 DOI: 10.1093/carcin/bgp327  0.56
2010 Lee JD, Hempel N, Lee NY, Blobe GC. The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling. Carcinogenesis. 31: 175-83. PMID 19955393 DOI: 10.1093/carcin/bgp271  0.36
2009 Lee NY, Kirkbride KC, Sheu RD, Blobe GC. The transforming growth factor-beta type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors. Molecular Biology of the Cell. 20: 4362-70. PMID 19726563 DOI: 10.1091/mbc.E09-07-0539  0.88
2009 Lee NY, Haney JC, Sogani J, Blobe GC. Casein kinase 2beta as a novel enhancer of activin-like receptor-1 signaling. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 23: 3712-21. PMID 19592636 DOI: 10.1096/fj.09-131607  0.36
2009 You HJ, How T, Blobe GC. The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2. Carcinogenesis. 30: 1281-7. PMID 19325136 DOI: 10.1093/carcin/bgp071  0.48
2009 Gordon KJ, Kirkbride KC, How T, Blobe GC. Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2 Carcinogenesis. 30: 238-248. PMID 19056927 DOI: 10.1093/carcin/bgn274  1
2008 Finger EC, Lee NY, You HJ, Blobe GC. Endocytosis of the type III transforming growth factor-beta (TGF-beta) receptor through the clathrin-independent/lipid raft pathway regulates TGF-beta signaling and receptor down-regulation. The Journal of Biological Chemistry. 283: 34808-18. PMID 18845534 DOI: 10.1074/jbc.M804741200  0.36
2008 Lee NY, Ray B, How T, Blobe GC. Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. The Journal of Biological Chemistry. 283: 32527-33. PMID 18775991 DOI: 10.1074/jbc.M803059200  0.48
2008 Gordon KJ, Blobe GC. Role of transforming growth factor-β superfamily signaling pathways in human disease Biochimica Et Biophysica Acta - Molecular Basis of Disease. 1782: 197-228. PMID 18313409 DOI: 10.1016/j.bbadis.2008.01.006  1
2008 Hempel N, How T, Cooper SJ, Green TR, Dong M, Copland JA, Wood CG, Blobe GC. Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta. Carcinogenesis. 29: 905-12. PMID 18299279 DOI: 10.1093/carcin/bgn049  1
2008 Kirkbride KC, Townsend TA, Bruinsma MW, Barnett JV, Blobe GC. Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor. The Journal of Biological Chemistry. 283: 7628-37. PMID 18184661 DOI: 10.1074/jbc.M704883200  0.88
2008 Finger EC, Turley RS, Dong M, How T, Fields TA, Blobe GC. TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis. 29: 528-35. PMID 18174241 DOI: 10.1093/carcin/bgm289  0.48
2008 Gordon KJ, Dong M, Chislock EM, Fields TA, Blobe GC. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis. 29: 252-62. PMID 17999987 DOI: 10.1093/carcin/bgm249  1
2007 You HJ, Bruinsma MW, How T, Ostrander JH, Blobe GC. The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation. Carcinogenesis. 28: 2491-500. PMID 17768179 DOI: 10.1093/carcin/bgm195  0.48
2007 Lee NY, Blobe GC. The interaction of endoglin with beta-arrestin2 regulates transforming growth factor-beta-mediated ERK activation and migration in endothelial cells. The Journal of Biological Chemistry. 282: 21507-17. PMID 17540773 DOI: 10.1074/jbc.M700176200  0.36
2007 Hempel N, How T, Dong M, Murphy SK, Fields TA, Blobe GC. Loss of betaglycan expression in ovarian cancer: role in motility and invasion. Cancer Research. 67: 5231-8. PMID 17522389 DOI: 10.1158/0008-5472.CAN-07-0035  1
2007 Czito BG, Bendell JC, Willett CG, Morse MA, Blobe GC, Tyler DS, Thomas J, Ludwig KA, Mantyh CR, Ashton J, Yu D, Hurwitz HI. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. International Journal of Radiation Oncology, Biology, Physics. 68: 472-8. PMID 17498568 DOI: 10.1016/j.ijrobp.2007.02.001  1
2007 Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Research. 67: 1090-8. PMID 17283142 DOI: 10.1158/0008-5472.CAN-06-3117  0.48
2007 Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC. The type III TGF-beta receptor suppresses breast cancer progression. The Journal of Clinical Investigation. 117: 206-17. PMID 17160136 DOI: 10.1172/JCI29293  1
2006 Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic malignancies. Blood. 107: 4589-96. PMID 16484590 DOI: 10.1182/blood-2005-10-4169  0.4
2006 Czito BG, Willett CG, Bendell JC, Morse MA, Tyler DS, Fernando NH, Mantyh CR, Blobe GC, Honeycutt W, Yu D, Clary BM, Pappas TN, Ludwig KA, Hurwitz HI. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 656-62. PMID 16446337 DOI: 10.1200/JCO.2005.04.1749  1
2005 Kirkbride KC, Ray BN, Blobe GC. Cell-surface co-receptors: emerging roles in signaling and human disease. Trends in Biochemical Sciences. 30: 611-21. PMID 16185874 DOI: 10.1016/j.tibs.2005.09.003  0.88
2005 Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer Journal of Clinical Oncology. 23: 2078-2093. PMID 15774796 DOI: 10.1200/JCO.2005.02.047  1
2003 Peri S, Navarro JD, Amanchy R, Kristiansen TZ, Jonnalagadda CK, Surendranath V, Niranjan V, Muthusamy B, Gandhi TK, Gronborg M, Ibarrola N, Deshpande N, Shanker K, Shivashankar HN, Rashmi BP, ... ... Blobe GC, et al. Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Research. 13: 2363-71. PMID 14525934 DOI: 10.1101/gr.1680803  1
2003 Chen W, Kirkbride KC, How T, Nelson CD, Mo J, Frederick JP, Wang XF, Lefkowitz RJ, Blobe GC. Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling. Science (New York, N.Y.). 301: 1394-7. PMID 12958365 DOI: 10.1126/science.1083195  1
2003 Kirkbride KC, Blobe GC. Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy. Expert Opinion On Biological Therapy. 3: 251-61. PMID 12662140 DOI: 10.1517/14712598.3.2.251  0.88
2002 Schiemann WP, Blobe GC, Kalume DE, Pandey A, Lodish HF. Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion. Fibulin-5 is induced by transforming growth factor-beta and affects protein kinase cascades. The Journal of Biological Chemistry. 277: 27367-77. PMID 12021267 DOI: 10.1074/jbc.M200148200  1
Show low-probability matches.